<?xml version="1.0" encoding="UTF-8"?>
<p>AZM may have anti‐inflammatory effects directly on epithelial cells, such as suppression of GM‐CSF release,
 <xref rid="rmv2163-bib-0099" ref-type="ref">
  <sup>99</sup>
 </xref> TNF,
 <xref rid="rmv2163-bib-0114" ref-type="ref">
  <sup>114</sup>
 </xref> inhibition of IL‐8 production
 <xref rid="rmv2163-bib-0118" ref-type="ref">
  <sup>118</sup>
 </xref> and modulation of the anti‐viral PRRs RIG‐I and MDA5.
 <xref rid="rmv2163-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref> AZM inhibition of AP‐1 activation reduces production of MUCA5C responsible for inflammation‐induced changes in airway mucus.
 <xref rid="rmv2163-bib-0071" ref-type="ref">
  <sup>71</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0122" ref-type="ref">
  <sup>122</sup>
 </xref> Macrolides inhibit airway epithelial cell mucus secretion
 <xref rid="rmv2163-bib-0123" ref-type="ref">
  <sup>123</sup>
 </xref> and directly inhibit neutrophil elastase.
 <xref rid="rmv2163-bib-0124" ref-type="ref">
  <sup>124</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0125" ref-type="ref">
  <sup>125</sup>
 </xref> Another effect of macrolides on airway epithelial cells observed in vitro is increased epithelial barrier integrity by alterations in tight junction proteins, including claudins.
 <xref rid="rmv2163-bib-0102" ref-type="ref">
  <sup>102</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0126" ref-type="ref">
  <sup>126</sup>
 </xref>
</p>
